Human Genome Epidemiology Literature Finder
|
Records 1 - 12 (of 12 Records) |
| Query Trace: Disease Progression and UGT1A1[original query] |
|---|
| Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. British journal of cancer 2012 May 106 (10): 1591-7. Jo J-C, Lee J-L, Ryu M-H, Chang H M, Kim M, Lee H J, Kim H-S, Shin J-G, Kim T-W, Kang Y |
| Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer chemotherapy and pharmacology 2013 Jan 71 (1): 85-92. Takahara Naminatsu, Nakai Yousuke, Isayama Hiroyuki, Sasaki Takashi, Satoh Yumiko, Takai Daiya, Hamada Tsuyoshi, Uchino Rie, Mizuno Suguru, Miyabayashi Koji, Mohri Dai, Kawakubo Kazumichi, Kogure Hirofumi, Yamamoto Natsuyo, Sasahira Naoki, Hirano Kenji, Ijichi Hideaki, Tada Minoru, Yatomi Yutaka, Koike Kazuhi |
| Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. Breast cancer (Tokyo, Japan) 2015 Jul 22 (4): 335-42. Otsuka Hiroko, Fujii Teruhiko, Toh Uhi, Iwakuma Nobutaka, Takahashi Ryuji, Mishima Mai, Takenaka Miki, Kakuma Tatsuyuki, Tanaka Maki, Shirouzu Kaz |
| UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan. Annals of hematology 2015 Jan 94 (1): 65-9. Yamasaki Satoshi, Tanimoto Kazuki, Kohno Kentarou, Kadowaki Masanori, Takase Ken, Kondo Seiji, Kubota Akira, Takeshita Morishige, Okamura Seiic |
| Investigation of prognostic value of polymorphisms within estrogen metabolizing genes in Lithuanian breast cancer patients. BMC medical genetics 2015 16 2. Savukaityt? Aist?, Ugenskien? Rasa, Jankauskait? Roberta, ?ereškevi?ius Darius, Šepetauskien? Egl?, Juozaityt? Elo |
| Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer. Journal of cancer research and therapeutics 0 12 (1): 193-7. Isaakidou Athina, Gazouli Maria, Aravantinos Gerasimos, Pectasides Dimitrios, Theodoropoulos George |
| Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting. Translational oncology 2019 Mar 12 (3): 502-512. Ma Cheng-Jen, Huang Ching-Wen, Chang Tsung-Kun, Tsai Hsiang-Lin, Su Wei-Chih, Yeh Yung-Sung, Chen Po-Jung, Wang Jaw-Yu |
| Genetic variants of UDP-glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary sclerosing cholangitis. Liver international : official journal of the International Association for the Study of the Liver 2020 Apr . Weismüller Tobias J, Zhou Taotao, Kalthoff Sandra, Lenzen Henrike, Manns Michael P, Strassburg Christian |
| UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI. Journal of oncology 2021 3 2021 6686517. Hsieh Yi-Chien, Chang Tsung-Kun, Su Wei-Chih, Huang Ching-Wen, Tsai Hsiang-Lin, Chen Yen-Cheng, Li Ching-Chun, Chen Po-Jung, Yin Tzu-Chieh, Ma Cheng-Jen, Wang Jaw-Yu |
| Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study. Thoracic cancer 2023 9 . Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke Ogata, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Katsumi Nakatomi, Fumiko Hayashi, Nanae Sugasaki, Akitoshi Kinoshita, Hiroshi Muk |
| Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101). Journal of clinical medicine 2023 2 12 (4): . Harada Kazuaki, Yamamura Takahiro, Muto Osamu, Nakamura Michio, Sogabe Susumu, Sawada Kentaro, Nakano Shintaro, Yagisawa Masataka, Muranaka Tetsuhito, Dazai Masayoshi, Tateyama Miki, Kobayashi Yoshimitsu, Kato Sosuke, Hatanaka Kazuteru, Kawamoto Yasuyuki, Yuki Satoshi, Sakata Yuh, Sakamoto Naoya, Komatsu Yoshi |
| UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan. Cancer medicine 2024 8 13 (16): e70096. Megan H Wong, Veronica C Jones, Wai Yu, Linda D Bosserman, Sayeh M Lavasani, Niki Patel, Mina S Sedrak, Daphne B Stewart, James R Waisman, Yuan Yuan, Joanne E Mortim |
- Page last reviewed:Feb 1, 2024
- Content source: